Patent application number | Description | Published |
20090074804 | VERO CELL-BASED INFLUENZA VIRUS STRAINS AND VACCINES - The present invention relates to isolated influenza virus strains suitable for increased vaccine production for mammals. The influenza virus strains contain at least one modified influenza protein that results in increased production of the influenza virus from a mammalian host cell, such as a vero cell. The present invention also relates to the vaccines produced from the influenza virus strains. The present invention further relates to isolated modified influenza proteins and isolated nucleic acid molecules that encode for the modified influenza proteins. | 03-19-2009 |
20090221499 | Lipidating Sequences and Use thereof for Producing Lipidated Proteins in E. Coli - Production in | 09-03-2009 |
20100166785 | ADJUVANTS - Disclosed are lipopeptides or lipoproteins, related compositions, and related methods. | 07-01-2010 |
20100172925 | HLA-A2-RESTRICTED T-CELL EPITOPES OF THE RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN AS PEPTIDE-BASED VACCINES - Respiratory syncytial virus (RSV) fusion protein-specific T-cell epitopes as peptide-based vaccines are disclosed. The isolated peptide contains a human HLA restricted CD8+ T-cell epitope that is specific to RSV F protein. The length of the peptide is no more than 9 or 10 amino acid residues. The peptide may be employed as an immunogen to stimulate cytotoxic T cells, indirectly activate helper T cells type 1, and cause release of cytokines from T cells. | 07-08-2010 |
20100272747 | POLYVALENT CHIMERIC RUBELLA VIRUS-BASED VACCINES - A chimeric viral particle that comprises a RV fusion gene is disclosed. The RV fusion gene comprises a first nucleotide sequence encoding a RV that is devoid of RV E1 protein, and a second nucleotide sequence that linked in translation frame to the first nucleotide sequence and encodes a humoral immunogenic viral protein. The chimeric viral particle is free of RV E1 protein-encoding gene. A virus packaging cell that generates the chimeric viral particle comprising a RV fusion gene and an isolated expression vector comprising a RV fusion gene linked in translation frame to a promoter are also disclosed. | 10-28-2010 |
20100303849 | Lipidated Vaccine against Dengue Virus Infection - Disclosed are immunogenic composition, fusion proteins, and related methods for inducing immune response to dengue virus infection. | 12-02-2010 |
20100322953 | Lipidated Tumor-Associated Antigens and Immunotherapeutic Compositions - Disclosed are polypeptides and fusion proteins. Also disclosed are related immunotherapeutic compositions and methods. | 12-23-2010 |
20110038894 | Immunogenic Peptides of Tumor Associated Antigen L6 and Uses Thereof in Cancer Therapy - An immunopeptide containing a T cell epitope from the tumor associated antigen L6 (TAL6) and a nucleic acid encoding the immunopeptide. The immunopeptide and its encoding nucleic acid can be used as a component of an immune composition for enhancing immune response against cancer cells that express TAL6. | 02-17-2011 |
20110052633 | MULTI-PHASE EMULSIONS BASED ON AMPHIPHILIC BLOCK COPOLYMERS - An composition comprises (a) a continuous aqueous phase; (b) an oily phase; and (c) an amphiphilic emulsifying system comprising a block copolymer having the formula (A)p-(B)q-(C)r, in which (B)q is a hydrophilic block and (C)r is a hydrophobic block; wherein p, q and r are integers with the proviso that: if p is 0, then A is other than hydroxyl or reactive functional groups and the block copolymer is a diblock copolymer; B and C are each individual repeating) units; if p is >1, then the block copolymer is a triblock copolymer, in which (A)p is a hydrophobic block; the hydrophobic blocks (A)p and (C)r are each homopolymers or heteropolymers; the repeating units A and C are the same or different; and wherein the ratio q/(p+r) is sufficient high so that the hydrophilic-lipophilic balance value of the block copolymer is >10. | 03-03-2011 |
20120045468 | Immunogenic Compositions and Uses Thereof - Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods. | 02-23-2012 |
20120328654 | MULTI-PHASE EMULSIONS BASED ON AMPHIPHILIC BLOCK COPOLYMERS - A method for enhancing a body's response to an immunogen is disclosed. The method comprises immunizing a subject in need thereof a vaccine composition in a water-in-oil (W/O/W) emulsion that comprises (a) an antigen; and (b) an adjuvant composition in a W/O/W emulsion. The adjuvant composition comprises: (i) a continuous aqueous phase comprising H | 12-27-2012 |
20130251748 | USE OF OUTER MEMBRANE PORIN K36 PROTEIN (OMPK36) IN TREATMENT/PREVENTION/DIAGNOSIS OF ENTEROBACTERIACEAE INFECTION - The present invention relates a method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by | 09-26-2013 |
20140056856 | IMMUNOSUPPRESSIVE CELLS AND METHODS OF MAKING AND USING THEREOF - This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine. | 02-27-2014 |
20140271700 | COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASES - Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of | 09-18-2014 |